Good MorningEquity markets reversed two days of losses to advance to a new high on Wednesday following better-than-expected economic data. Investors cheered hot ISM services and Factory Orders data suggesting both aspects of the US economy are regaining momentum. If true, investors should also expect another uptick in inflation as demand puts added pressure on the economy.
In other news, oil prices continue to slide and fall below key support at the $96 level following a slight increase in production from OPEC. This move may trigger additional selling, but the worse news is the implication for the economy. Oil prices are not expected to contract without a major slow down in activity, and we've yet to see one. In this light, the decline in oil prices is either a precursor to a deeper economic recession or a whipsaw move and buying opportunity. Featured: Watch These 4 Penny Stocks... (PTR) 
|
Stocks | | |
Typically when a mature company’s share price is hovering around $20 or below, it means that growth prospects are limited. But that’s not always the case.
As we’ve seen during this year’s market downturn, even well-run, fundamentally sound companies can get dragged down wi... Read the Full Story |
|
From Our PartnersOne of the best ways to spot potential opportunity is by tracking insiders.
After all, who knows the company better than an insider - the CEO, CFO, COO, officers, employees, and directors? If they're buying a sizable number of shares, it's often a good idea to start looking into why and perhaps follow them into the stock. Here are five stocks seeing a good share of insider buying in recent weeks. | | Click Here to Download the FREE Report |
|
Politics | | | Stocks on Wall Street closed broadly higher Wednesday as investors welcomed encouraging economic data and quarterly earnings reports from big companies including Starbucks.
The S&P 500 rose 1.6% to an almost 2-month high, while the Nasdaq gained 2.6%. Both indexes more than recoup... Read the Full Story |
|
Politics | | | Stocks on Wall Street are extending their gains in afternoon trading Wednesday as investors review a mostly encouraging batch of quarterly earnings from several big companies.
The S&P 500 rose 1.7% as of 3:02 p.m. Eastern. The Dow Jones Industrial Average rose 453 points, or 1.4%,... Read the Full Story |
|
From Our PartnersNot sure what’s going to happen next in these markets? Look to history. In 2004-2006, we saw backbreaking inflation run rampant just like today. And what happened next? An historic bull market. The deck is stacking again for another bull market - and it could dwarf the last one.
(**By clicking link you are subscribing to The American Wealth Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.) | | Go HERE to learn how to make out like a bandit in |
|
Stocks | | |
Devon Energy (NYSE:DVN) may be an overlooked company in the oil and gas sector. However, that may change after the company releases earnings this week. The $5.63 billion in revenue beat expectations by 18%. And on the bottom line, the news was equally impressive, with the company posting $2.59 ear... Read the Full Story |
|
Stocks | | |
The health care sector is just barely participating in the S&P 500’s nascent rally, but pharmaceuticals such as AbbVie (NYSE:ABBV), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) are holding up well relative to the broader market.
All three reported earnings recently, and while none got a... Read the Full Story |
|
From Our PartnersLooking for a simple way to address inflation, hedge against economic uncertainty and gain more peace of mind fast?
For decades, many of the world's savviest, smartest and richest people have turned to gold because Governments can't devalue it by printing more of it out of thin air, you can store it safely in a vault, and it rises in value when the markets fall. | | For a limited time, you can get a FREE copy NEW, Inflation Survival Kit by clicking HERE |
|
Stocks | | |
Media entertainment company Warner Brothers Discovery (NYSE: WBD) stock has languished since its spin-off as it fell to new all-time lows at $12.77 and down (-41%) year-to-date. Formerly Discovery Networks, the merging with WarnerMedia has created a content powerhouse including popular brands like... Read the Full Story |
|
Markets | | |
The entire energy infrastructure complex is moving higher and Energy Transfer LP (NYSE: ET) may lead the bunch. The company’s diversified approach to energy and its reliance on fee-based income make it stand out from other energy companies and its own peers. Trading at 7.33X its earnings it ... Read the Full Story |
|
Tech | | | Toyota’s profit fell nearly 18% in the April-June quarter from the year before, as a semiconductor shortage that has slammed the auto industry dented production at Japan’s top automaker.
Toyota Motor Corp. reported Thursday a quarterly profit of 736.8 billion yen ($5.5 billion), down... Read the Full Story |
|
Politics | | | President Joe Biden traveled to Saudi Arabia last month on the possibility that he could get some additional oil production out of OPEC+ in coming weeks, but the cartel and other nations announced a scant increase Wednesday.
The White House responded by stressing that what matters is ... Read the Full Story |
|
Politics | | | President Joe Biden traveled to Saudi Arabia last month on the possibility that he could get some additional oil production out of OPEC+ in coming weeks — but the cartel and other nations announced a scant increase on Wednesday.
The White House responded by stressing that what matters... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. | | View Today's Stock Pick |
|
